Primary cardiac angiosarcoma - a review.
Primary cardiac neoplasms are extremely rare. Angiosarcoma is the most commonly seen histological subtype and is characterized by its permeating and destructive nature. Unfortunately, primary cardiac angiosarcoma is often overlooked as an initial diagnosis because of its rarity. Since the time it was first identified in 1934, little progress has been made in improving survival outcome. Complete or partial surgical resection is still the best option for palliation, with little hope for cure. Improvements have been made in the ability to view and distinguish tumors. Echocardiography is one of the most useful diagnostic tools because of its high sensitivity; therefore, CT and MR images are often used to detect sites of metastatic disease. Immunohistochemistry staining can also be employed as an adjunctive diagnostic tool. CD31, CD34, FLI-1, and von Willebrand factor are the most commonly used markers in detecting tumors of endothelial origin. However, due to the vast heterogeneity within a tumor, immunohistochemistry staining can be quite variable. Surgical resection remains the standard modality of treatment. Primary cardiac angiosarcoma is largely resistant to chemotherapy and/or radiation. However, the exact benefit and its place in a multimodality treatment regimen are still under investigation.
Department of Anatomical Sciences, St. George's University School of Medicine, St. George, Grenada.
Swetal Dilip
SD
Patel
Department of Anatomical Sciences, St. George's University School of Medicine, St. George, Grenada.
Ashley
A
Peterson
Department of Pathology, Medical Centre of Postgraduate Education, Warsaw, Poland.
Artur
A
Bartczak
Department of Anatomical Sciences, St. George's University School of Medicine, St. George, Grenada.
Sarah
S
Lee
Department of Cardiology, Bielanski Hospital, Warsaw, Poland.
Sławomir
S
Chojnowski
Department of Cardiology, Bielanski Hospital, Warsaw, Poland.
Piotr
P
Gajewski
Department of Anatomical Sciences, St. George's University School of Medicine, St. George, Grenada.
Marios
M
Loukas
D018952:Antigens, CD34 / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D004452:Echocardiography; D006338:Heart Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D006394:Hemangiosarcoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D006801:Humans; D007150:Immunohistochemistry; D008840:Microfilament Proteins / Q000378:metabolism; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D015534:Trans-Activators; D014841:von Willebrand Factor / Q000378:metabolism
D018952:Antigens, CD34; D014408:Biomarkers, Tumor; C098179:FLII protein, human; D008840:Microfilament Proteins; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D018160:Receptors, Cytoplasmic and Nuclear; D015534:Trans-Activators; D014841:von Willebrand Factor